The possibilities of therapy of patients with metastatic colorectal cancer with BRAF V600E mutation. Clinical cases

封面

如何引用文章

全文:

详细

Mutation in the BRAF V600E gene in metastatic colorectal cancer (CRC) occurs in 5–10% of cases and is a significant problem due to the aggressive course and extremely unfavorable prognosis. In recent years, new treatment options for BRAF mutated CRC have been emerging, for example, combinations of BRAF inhibitors, anti-EGFR antibodies with optional addition of MEK inhibitors. The possibility of local treatment methods is also being discussed. Objective: to evaluate the effectiveness of triple targeted therapy in BRAF-mutated metastatic colorectal cancer. On the example of 2 clinical cases of long-term treatment of patients with this molecular subtype, possible treatment options are discussed.

作者简介

Elizaveta Polyanskaya

Blokhin National Medical Research Center of Oncology

编辑信件的主要联系方式.
Email: lazimira@mail.ru
ORCID iD: 0000-0001-7193-1169

Oncologist, Blokhin National Medical Research Center of Oncology

俄罗斯联邦, Moscow

Mikhail Fedyanin

Blokhin National Medical Research Center of Oncology; Moscow Multidisciplinary Clinical Center “Kommunarka“; Pirogov National Medical and Surgical Center

Email: fedianinmu@mail.ru
ORCID iD: 0000-0001-5615-7806

D. Sci. (Med.), Blokhin National Medical Research Center of Oncology, Moscow Multidisciplinary Clinical Center “Kommunarka“, Pirogov National Medical and Surgical Center

俄罗斯联邦, Moscow; Moscow; Moscow

参考

  1. Sung H, Ferlay J, Siegel RL, Ferlay J. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. Cancer J Clin. 2021;71(3):209-24. doi: 10.3322/caac.21660
  2. Riihimäki M, Hemminki A, Sundquist J, Hemminki K. Patterns of metastasis in colon and rectal cancer. Sci Rep. 2016;6(1):29765. doi: 10.1038/srep29765
  3. Федянин М.Ю., Эльснукаева Х.М., Демидова И.А., и др. Колоректальный рак с мутацией в гене BRAF в Российской федерации: эпидемиология и клинические особенности. Результаты многоцентрового исследования. Медицинский совет. 2021;(4S):52-63 [Fedyanin MYu, Ehlsnukaeva КM, Demidova IA, et al. Incidence and prognostic factors in patents (pts) with mutant BRAF (mBRAF) metastatic colorectal cancer (mCRC) in Russia. Medical Council. 2021;(4S):52-63 (in Russian)].
  4. Chu JE, Johnson B, Morris VK, et al. Population-based screening for BRAF V600E in metastatic colorectal cancer (mCRC) to reveal true prognosis. J Clin Oncol. 2019;37(15_suppl):3579. doi: 10.1200/JCO.2019.37.15_suppl.3579
  5. Modest DP, Ricard I, Heinemann V, et al. Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group. Ann Oncol. 2016;27(9):1746-53. doi: 10.1093/annonc/mdw261
  6. Kopetz S, Grothey A, Yaeger R, et al. Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer. N Engl J Med. 2019;381(17):1632-43. doi: 10.1056/NEJMoa1908075
  7. Loree JM, Pereira AAL, Lam M, et al. Classifying Colorectal Cancer by Tumor Location Rather than Sidedness Highlights a Continuum in Mutation Profiles and Consensus Molecular Subtypes. Clin Cancer Res. 2018;24(5):1062-72. doi: 10.1158/1078-0432.CCR-17-2484
  8. Огнерубов Н.А., Ежова Е.Н. Соматические мутации при колоректальном раке: опыт региона. Consilium Medicum. 2022;24(5):291-6 [Ognerubov NA, Ezhova EN. Somatic mutations in colorectal cancer: regional experience. Consilium Medicum. 2022;24(5):291-6 (in Russian)]. doi: 10.26442/20751753.2022.5.201796
  9. Wang X. KRAS, BRAF and PIK3CA mutations in human colorectal cancer: Relationship with metastatic colorectal cancer. Oncol Rep. 2011;25(6):1691-7. doi: 10.3892/or.2011.1217
  10. Hernández-Sandoval JA, Gutiérrez-Angulo M, Magaña-Torres MT, et al. Prevalence of the BRAF p.v600e variant in patients with colorectal cancer from Mexico and its estimated frequency in Latin American and Caribbean populations. J Investig Med. 2020;68(5):985-91. doi: 10.1136/jim-2020-001301
  11. Федянин М.Ю., Полянская Е.М., Эльснукаева Х.Х., и др. Метаанализ исследований по сравнению эффективности режимов FOLFOXIRI и FOLFOX или FOLFIRI с таргетной терапией при метастатическом раке толстой кишки с мутацией в гене BRAF. Медицинский Совет. 2020;20:125-32 [Fedyanin MYu, Polyanskaya EM, Elsnukaeva HH, et al. FOLFOXIRI versus FOLFOX or FOLFIRI with targeted therapy in patients with mutant BRAF metastatic colorectal cancer: A systematic review and meta-analysis. Med Council. 2020;20:125-32 (in Russian)]. doi: 10.21518/2079-701X-2020-20-125-132
  12. Shimozaki K, Hirata K, Sato T, et al. WJOG13219G: Triplet versus doublet in patients with previously untreated BRAFV600E-mutant metastatic colorectal cancer: A multi-institutional real-world data analysis (BRACELET study). J Clin Oncol. 2022;40(4_suppl):37. doi: 10.1200/JCO.2022.40.4_suppl.037
  13. Cohen R, Liu H, Fiskum J, et al. BRAF V600E Mutation in First-Line Metastatic Colorectal Cancer: An Analysis of Individual Patient Data From the ARCAD Database. JNCI J Natl Cancer Inst. 2021;113(10):1386-95. doi: 10.1093/jnci/djab042
  14. Stintzing S, Heinrich K, Tougeron D, et al. Randomized study to investigate FOLFOXIRI plus either bevacizumab or cetuximab as first-line treatment of BRAF V600E-mutant mCRC: The phase-II FIRE-4.5 study (AIO KRK-0116). J Clin Oncol. 2021;39(Suppl. 15):3502. doi: 10.1200/JCO.2021.39.15_suppl.3502
  15. Tabernero J, Grothey A, Van Cutsem E, et al. Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E-Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study. J Clin Oncol. 2021;39(4):273-84. doi: 10.1200/JCO.20.02088
  16. Takashima A, Kotani D, Kato T, et al. Safety and efficacy of encorafenib, binimetinib, plus cetuximab for BRAF V600E-mutant metastatic colorectal cancer: Results of a prospective study as an expanded access program. J Clin Oncol. 2022;40(4_suppl):199. doi: 10.1200/JCO.2022.40.4_suppl.199
  17. Kopetz S, Aderka D, Grothey A, et al. Overall survival (OS) with encorafenib (enco) + cetuximab (cetux) in BEACON CRC: Effect of prior therapy for BRAF V600E-mutant metastatic colorectal cancer (mCRC). J Clin Oncol. 2021;39(15_suppl):3583. doi: 10.1200/JCO.2021.39.15_suppl.3583
  18. Hafliger E, Boccaccino A, El-Khoury R, et al. 440P Response to BRAF inhibitors combined with anti-EGFR after previous anti-EGFR exposure for BRAF V600E mutant metastatic colorectal cancer patients. Ann Oncol. 2021;32:S554. doi: 10.1016/j.annonc.2021.08.961
  19. Van Cutsem E, Taieb J, Yaeger R, et al. O-10 ANCHOR CRC: Results from a single-arm, phase 2 study of encorafenib, binimetinib plus cetuximab in previously untreated BRAF V600E-mutant metastatic colorectal cancer. Ann Oncol. 2021;32:S222. doi: 10.1016/j.annonc.2021.05.014
  20. Kopetz S, Yoshino T, Kim TW, et al. BREAKWATER safety lead-in (SLI): Encorafenib + cetuximab (EC) ± chemotherapy for first-line (1L) treatment (tx) of BRAF V600E-mutant (BRAF V600E) metastatic colorectal cancer (mCRC). J Clin Oncol. 2022;40(4_suppl):134. doi: 10.1200/JCO.2022.40.4_suppl.134
  21. Morris VK, Parseghian CM, Escano M, et al. Phase I/II trial of encorafenib, cetuximab, and nivolumab in patients with microsatellite stable, BRAF V600E metastatic colorectal cancer. J Clin Oncol. 2022;40(4_suppl):12. doi: 10.1200/JCO.2022.40.4_suppl.012
  22. Fedyanin M, Elsnukaeva K, Demidova I, et al. Metastasectomy in colorectal carcinoma (CRC) patients (pts) with mBRAF: Prospective database analysis. J Clin Oncol. 2021;39(15_suppl):e15549. doi: 10.1200/JCO.2021.39.15_suppl.e15549
  23. Osterlund PJ, Osterlund E, Uutela A, et al. Resectability, conversion and resections rates, and outcomes in RAS & BRAF wildtype (wt), RAS mutant (mt) and BRAF mt metastatic colorectal cancer (mCRC) subgroups in the prospective Finnish RAXO-study. J Clin Oncol. 2021;39(15_suppl):3532. doi: 10.1200/JCO.2021.39.15_suppl.3532
  24. Morón García B, Alva Bianchi M, Muñoz Martín AJ, et al. Clinical evolution after surgery of hepatic metastases of colorectal cancer according to genomic profile. J Clin Oncol. 2022;40(4_suppl):188. doi: 10.1200/JCO.2022.40.4_suppl.188
  25. Ros Montañá J, Martini G, Baraibar I, et al. Patient and tumor characteristics as determinants of overall survival (OS) in BRAF V600 mutant (mt) metastatic colorectal cancer (mCRC) treated with doublet or triplet targeted therapy. J Clin Oncol. 2020;38(15_suppl):4112. doi: 10.1200/JCO.2020.38.15_suppl.4112

补充文件

附件文件
动作
1. JATS XML
下载
2. Fig. 1. Overall survival results: a – ENCO/BINI/CETUX versus control, b – ENCO/CETUX versus control.

下载 (224KB)
索引源数据

版权所有 © Consilium Medicum, 2023

Creative Commons License
此作品已接受知识共享署名-非商业性使用-相同方式共享 4.0国际许可协议的许可。
 


##common.cookie##